Form 4: Cyclo Therapeutics Director Acquires Shares in Lieu of Cash Compensation

Director C.E. Rick Strattan acquired 30,169 shares of Cyclo Therapeutics common stock in lieu of cash compensation.

Summary

• C.E. Rick Strattan, a director of Cyclo Therapeutics, Inc., acquired 30,169 shares of common stock on February 27, 2025.
• The shares were received in lieu of cash compensation for director services.
• This compensation covers the fourth quarter of 2024 and the period from January 1, 2025, through March 25, 2025.
• The number of shares was calculated based on a price of $0.77 per share on February 26, 2025.
• Following the transaction, Strattan directly owns 399,272 shares of Cyclo Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director taking shares instead of cash can be seen as a vote of confidence, but it's a routine transaction.

Positives

• The director's decision to take shares in lieu of cash compensation could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Directors receiving stock in lieu of cash compensation is a fairly common practice, especially for smaller companies, as it helps conserve cash and aligns the director's interests with those of shareholders.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with shareholder value.

Key Dates